ARS Pharmaceuticals (SPRY) Stock Price, Quote, News & History | Benzinga

SPY777.81−0.04%QQQ742.43−0.48%BTC/USD82,969.33+1.51%DIA516.72−0.23%GLD381.28−0.23%TLT78.34+0.37%

ARS Pharmaceuticals Inc (SPRY) Stock Price, Quote, News & History

SPRYNASDAQ

Trade with Public

Trade with Public

$4.10

-0.08-1.91%

Last update: Oct 13, 2:40 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$4.18

Close

-

Volume / Avg.

1.01M / 1.84M

Day Range

$4.10 - $4.10

52 Wk Range

3.99 - 13.15

Market Cap

$415.69M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

38

Short Interest

30.72%

Days to Cover

16.1

Recent ARS Pharmaceuticals, Inc. News

Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures mixed, Dow down 0.1%. Swarmer Inc (NASDAQ: SWMR) shares drop 7% after reporting worse-than-expected financial results.

Avi Kapoor

Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.

Avi Kapoor

Can ARS Pharma's New CEO Unlock Neffy's Potential?

ARS Pharma (SPRY) co-founder Richard Lowenthal steps down as CEO. President Donn Casale succeeds him amid a strategic shift.

Vandana Singh

Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc (NASDAQ: FCEL) up 17.6%, BitVentures Limited (NASDAQ: BVC) up 14.1%, and ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) up 10.3% after receiving a positive recommendation for a market authorization in Europe.

Avi Kapoor

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins

ARS Pharma reaffirmed its 2027 breakeven target, cut expenses and gained Florida Medicaid access for Neffy despite coverage setbacks.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-196.41M

Investing Cash Flow (TTM)

48.50M

Financing Cash Flow (TTM)

104.53M

Free Cash Flow (TTM)

-196.60M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-43.38M

Analyst Trends and Forecast

1

May

1

Jun

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$373.49M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.54

PB Ratio (TTM)

33.22

Earnings Yield % (TTM)

-52.15%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.13

Company Debt

Total Debt

$96.68M

LT Debt

$96.68M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$8.16M

Debt to Equity

7.73

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-